KẾT QUẢ HÓA TRỊ PHÁC ĐỒ PACLITAXEL – CARBOPLATIN TRÊN BỆNH NHÂN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN IIIB- IV TẠI BỆNH VIỆN ĐA KHOA BẮC NINH

Abstract

Objectives: To describe some general characteristics and evaluate the effectiveness of the Paclitaxel-Carboplatin regimen in patients with stage IIIB-IV non-small cell lung cancer. Subjects: 48 patients with stage IIIB-IV non-small cell lung cancer receiving first-line treatment with Paclitaxel-Carboplatin regimen at Bac Ninh General Hospital. The period is from January 2019 to April 2022. Methods: Retrospective, descriptive, cross-sectional descriptive study with longitudinal follow-up. Results: The mean age in the study was 62.5 ± 6.78. The male/female ratio is 5/1. Adenocarcinoma accounted for 89.6%. Disease in stage IV accounted for 70.8%. The functional response rate was 81.3%, the overall response rate was 27.1%, the disease control rate was 62.5%; Median PFS was 5,9 months, PFS was 7,8 ± 1,2 (months). Conclusion: Chemotherapy with Paclitaxel-Carboplatin regimen in the first-line treatment of NSCLC stage IIIB- IV improves functional symptoms, gives high disease control rate, prolongs progression-free survival, toxicity acceptable.